| abstract |
The present disclosure provides compounds represented by Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein R8, R<SP>9a</SP>, R<SP>9b</SP>, R<SP>9c</SP>, R<SP>9d</SP>, X, Y, Z, Z1, W, and are as defined as set forth in the specification. The presentdisclosure also provides compounds of Formula I-A for use to treat a condition or disorder responsive to Mcl-1 inhibition such as cancer. |